Data from the phase 1/2 Beacon trial indicated that Beam-101, the company’s sickle cell therapy, increased fetal hemoglobin levels from an initial range of 4% to 17% to levels of 72% to 74% within two months. Hemoglobin levels remained elevated for two patients at five- and six-month follow-ups.
One patient died four months after the Beam-101 infusion due to respiratory failure. The death was likely related to busulfan conditioning and was determined to be unrelated to the treatment itself.
No other grade 3 or higher adverse events or serious adverse events related to the treatment were reported.
Beam Therapeutics plans to expand the trial to a cohort of 42 participants.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
